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Abstract
Introduction:  There  has  been  an  increase  in  the  incidence  of  hepatocellular  carcinoma  (HCC)
worldwide  and  information  on  this  disease  is  limited  in  Mexico.
Aims:  To  analyze  the  available  evidence  on  the  diagnosis  and  treatment  of  HCC  in  the  Mexican
population.
Material  and  methods:  The  Mexican  Association  of  Hepatology  organized  a  meeting  that  24
medical specialists  interested  in  HCC  attended.  An  electronic  database  search  was  carried  out
to identify  documents  published  from  2000  with  the  keywords  «Hepatocellular  carcinoma» and
«Mexico», «epidemiology»,  «diagnosis»,  and  «treatment».
Results:  The  incidence  of  HCC  in  Mexico  has  increased  over  the  last  few  decades.  The  mean  age
of disease  presentation  is  in  patients  from  60  to  70  years  old,  and  the  man:woman  ratio  appears
to be  equal.  HCC  is  frequently  associated  with  underlying  hepatopathy  and  the  primary  cause
reported in  our  country  is  chronic  hepatitis  C  virus)  infection.  Surveillance  is  recommended  for
high-risk groups  in  Child-Pugh  stages  A  and  B,  and  for  those  in  stage  C  if  the  patient  is  on  a
waiting list  or  regarded  as  a  candidate  for  liver  transplantation.  HCC  should  be  evaluated  by
a multidisciplinary  team  of  experts  in  the  ﬁeld. Please cite this article as: González Huezo MS, Sánchez Ávila JF, en representación de Asociación Mexicana de Hepatología, Asociación
exicana de Gastroenterología, Sociedad Mexicana de Radiología e Imagen, Sociedad Mexicana de Oncología, World Gastroenterology Organi-
ation, Grupo Mexicano de Consenso de Carcinoma Hepatocelular. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular.
evista de Gastroenterología de México. 2014;79:250--262.
∗ Corresponding author: Asociación Mexicana de Hepatología, Nicolás San Juan 233, Col. del Valle, Benito Juárez, C.P. 03100 Cd. de México,
istrito Federal. Phone number: +01 55 5639 4033.
E-mail address: amh@hepatologia.org.mx (M.S. González Huezo).
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Conclusions:  HCC  is  a  neoplasia  that  is  on  the  rise  in  Mexico,  with  epidemiologic  characteris-
tics similar  to  those  of  other  populations.  Diagnosis  and  treatment  should  be  individualized  in
accordance  with  these  Consensus  guidelines.
© 2013  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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Consenso  mexicano  de  diagnóstico  y  manejo  del  carcinoma  hepatocelular
Resumen
Introducción:  La  incidencia  del  carcinoma  hepatocelular  (CHC)  ha  presentado  un  aumento  a
nivel global  y  en  México  existe  información  limitada  sobre  la  enfermedad.
Objetivo:  Analizar  la  evidencia  disponible  en  población  mexicana  sobre  el  diagnóstico  y
tratamiento  del  CHC.
Material  y  métodos:  La  Asociación  Mexicana  de  Hepatología  convocó  a  una  reunión  donde  par-
ticiparon 24  médicos  especialistas  con  interés  en  CHC.  Se  realizó  una  búsqueda  en  bases  de
datos electrónicas  para  identiﬁcar  documentos  publicados  a  partir  del  2000  con  los  térmi-
nos «Carcinoma  hepatocelular» y  «México» agregando  además  términos  como:  epidemiología,
diagnóstico  y  tratamiento.
Resultados:  La  incidencia  de  CHC  en  México  se  ha  incrementado  en  las  últimas  décadas.  En
México la  edad  promedio  de  presentación  se  sitúa  en  la  década  de  los  sesenta  y  la  relación
femenino:masculino  parece  ser  igual.  El  CHC  se  asocia  frecuentemente  a  hepatopatía  subya-
cente y  la  principal  causa  reportada  en  nuestro  país  es  la  infección  crónica  por  el  virus  de  la
hepatitis C.  La  vigilancia  se  recomienda  a  grupos  de  alto  riesgo  en  estadios  A  y  B  de  Child-Pugh,
y en  estadio  C  solo  si  se  encuentra  en  lista  de  espera  o  se  considera  candidato  a  trasplante
hepático. El  CHC  debe  ser  evaluado  por  un  equipo  multidisciplinario  de  expertos  en  el  área.
Conclusiones:  El  CHC  representa  una  neoplasia  que  va  en  aumento  en  nuestro  país  con  carac-
terísticas epidemiológicas  similares  a  otras  poblaciones.  El  diagnóstico  y  el  tratamiento  deben
de individualizarse  de  acuerdo  a  lo  mostrado  en  estas  guías.
© 2013  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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IThe  incidence  of  hepatocellular  carcinoma  (HCC)  has
increased  worldwide  and  in  Mexico  there  is  limited  informa-
tion  about  this  disease,  its  survival  rates,  and  its  treatment.
The  aim  of  this  work  was  to  analyze  the  available  evidence
on  the  Mexican  population  in  relation  to  the  diagnosis  and
treatment  of  HCC  within  the  framework  established  by  the
current  international  clinical  and  therapeutic  guidelines  for
this  pathology.  The  Mexican  Association  of  Hepatology  orga-
nized  a  meeting  in  November  2012  in  Merida,  Yucatan,  that
was  attended  by  24  specialized  physicians  with  a  speciﬁc
interest  in  HCC.  The  physicians  were  invited  through  their
respective  medical  associations  to  participate  in  the  discus-
sion  of  the  different  disciplines  involved  in  the  diagnosis  and
management  of  HCC  that  included:  gastroenterology,  hep-
atology,  radiology,  pathology,  medical  oncology,  and  liver
surgery  and  transplantation.
MethodologyDocuments  published  from  2000  were  identiﬁed  through
electronic  database  searches  using  the  keywords
«hepatocellular  carcinoma» and  «Mexico» and  adding
terms  such  as:  epidemiology,  diagnosis,  and  treatment.
t
d
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carlier  documents  were  included  if  they  were  considered
aluable  for  the  current  analysis,  as  well  as  abstracts  pre-
ented  in  national  medical  congresses  that  provided  data  of
nterest  for  the  present  review.  The  international  clinical
nd  therapeutic  guidelines  published  by  the  American  and
uropean  associations  on  this  subject  were  added  to  the
ibliography,  along  with  articles  that  were  regarded  as
seful  for  the  elaboration  of  the  present  consensus.  The
ibliographic  information  was  sent  to  the  participants  to  be
eviewed  prior  to  the  meeting.
The  consensus  panel  was  divided  into  the  following  4
orking  groups  made  up  of  the  different  specialists  in  each
f  the  topics:
I  Epidemiology  and  risk  groups
II  Surveillance  and  diagnosis
II  Curative  treatment
V  Non-curative  treatment
A  document  was  produced  for  each  topic  according  to
he  available  evidence  and  contributions  from  each  of  the
isciplines,  with  their  respective  references.  Each  working
roup  presented  its  assessment  to  the  entire  panel  for  dis-
ussion,  after  which  key  statements  for  each  theme  were
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laborated.  These  statements  were  then  put  to  the  consid-
ration  of  the  participants  through  a  Delphi  panel,  grading
hem  as  follows:
 6  pts.  In  complete  agreement
 5  pts.  In  agreement
 4  pts.  In  partial  agreement
 3  pts.  In  partial  disagreement
 2  pts.  In  disagreement
 1  pt.  In  complete  disagreement
When  a  statement  was  graded  as  disagreement  (1  to  3
oints),  an  explanatory  motive  was  requested.
Agreement  >  70%  in  the  responses  was  regarded  as
onsensus.  Twenty-three  of  the  24  reunion  participants
nswered  the  questionnaire  and  the  omission  of  a  statement
esponse  was  considered  disagreement.  The  document  with
he  key  statements  and  their  levels  of  agreement  in  number
nd  percentage  is  presented  below.
. Epidemiology and risk groups
.S.  González-Huezo,  C.  Hernández  Hernández,  R.  Malé
elázquez,  N.  Méndez-  Sánchez,  R.  Moreno  Alcántar,  M.
amos  Gómez
pidemiology
rimary  liver  cancer  represents  approximately  4%  of  all
ew  cancers  diagnosed  worldwide,  and  of  all  the  neoplasias
riginating  in  the  liver,  approximately  90%  correspond  to
epatocellular  carcinoma.1
There  has  been  a  global  increase  in  hepatocellular  carci-
oma  incidence  over  the  last  few  decades;  it  is  the  ﬁfth
ost  frequent  neoplasia  and  the  third  cause  of  cancer-
elated  death.  The  greatest  prevalence  is  in  Asia  and  Africa,
hereas  prevalence  is  much  lower  in  America  and  Europe.2
n  the  United  States,  the  Hispanic  population  has  experi-
nced  the  greatest  annual  percentage  increase  in  the  last
ecade.  Compared  with  other  ethnic  groups,  this  popula-
ion  presented  an  important  increase  and  according  to  a
tudy  by  El-Serag  et  al.  encompassing  the  decade  of  1992
o  2002,  women  predominated  at  63%,  compared  with  31%
or  men.3 This  was  conﬁrmed  by  Alterkruse  et  al.4 in  their
nalysis  of  death  certiﬁcates  in  the  U.S.  Hispanic  population
arried  out  from  1975  to  2005.  They  also  reported  a  triplica-
ion  of  hepatocellular  carcinoma  in  this  population,  ﬁnding
n  annual  percentage  increase  of  4%  within  their  study  time
rame.  It  is  striking  that  40%  of  the  Hispanics  included  in  the
nalysis  were  born  outside  of  the  United  States  and  that  the
ncrease  in  this  disease  was  greater  in  native  Hispanics  than
n  their  immigrant  peers.
A  rise  in  incidence  of  this  pathology  has  been  observed  in
exico  for  several  decades.  Cortes-Espinosa  et  al.5 demon-
trated  that  incidence  doubled  within  a  25-year  period
1965-1990).  They  obtained  this  datum  through  a  necropsy
nalysis  (n  =  12,556)  at  a  referral  hospital  in  Mexico  City
0.35%  for  1965-1969  vs  0.69%  in  1985-1989).  More  recently,
éndez-Sánchez  et  al.6 analyzed  ofﬁcial  death  certiﬁcates
n  Mexico  from  the  year  2000  to  2006  and  reported  a  national
ncrease  of  14%  in  the  death  rate  from  HHC  (4.16  deaths  per
i
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sM.S.  González  Huezo,  J.F.  Sánchez  Ávila
00,000  inhabitants  in  the  year  2000  vs  4.74  in  2005).  Women
xperienced  the  greatest  change,  with  a  15%  increase,  com-
ared  with  the  12.5%  increase  in  men.  And  ﬁnally,  the
exican  National  Health  Information  System  (available  at
ww.sinais.salud.gob.mx)  analyzed  causes  of  death  from
979  to  2008  in  the  population  and  corroborated  an  increase
n  mortality  from  this  disease  from  0.4%  in  the  1980s  to  1.3%
or  2008.  According  to  the  available  information,  the  age
roups  above  55  years  are  the  most  affected,  with  an  equal
ortality  rate  for  men  and  women.
isk  Groups
able  1  presents  the  data  from  the  published  series  in  both
he  texts  and  abstracts  on  patients  with  HCC  and  its  pri-
ary  epidemiologic  characteristics.  In  relation  to  sex,  the
nternational  literature  generally  describes  a  predominance
n  men;  according  to  the  national  information  presented
y  different  authors6--10 and  recent  international  epidemi-
logic  reports,3,4 predominance  has  been  equaling  out  over
he  last  decade  and  may  possibly  increase  for  women  in  the
uture.  According  to  the  international  literature,  the  most
ffected  age  groups  are  persons  in  the  seventh  decade  of  life
n  regions  with  low  prevalence  and  from  the  sixth  decade  of
ife  in  regions  with  high  prevalence.  In  Mexico,  as  shown
n  table  1,  hepatocellular  carcinoma  presents  mainly  in  the
ixth  decade  of  life.  The  main  risk  factor  for  70  to  90%  of
he  patients  with  HCC  is  cirrhosis  of  the  liver.  Currently,  the
wo  main  causes  of  cirrhosis  of  the  liver  in  Mexico  are  alco-
olic  liver  disease  (39.5%)  and  hepatitis  C  virus  infection
36.6%);  to  a lesser  degree  are  cryptogenic  cirrhosis  (10.4%),
rimary  biliary  cirrhosis  (5.7%),  hepatitis  B  virus  (5%),  and
ther  reported  causes  (2.8%).11 It  is  noteworthy  that  cryp-
ogenic  cirrhosis  has  been  catalogued  as  the  third  cause  in
elation  to  cirrhosis  frequency,  which  could  correspond  to
onalcoholic  fatty  liver  disease,  given  its  strong  association
ith  obesity,  diabetes  mellitus,  and  dyslipidemia.
Before  the  discovery  of  the  hepatitis  C  virus,  2  case  series
ublished  in  Mexico  described  alcoholic  liver  disease  as  the
ain  risk  factor  for  HCC.7,12 After  its  identiﬁcation,  differ-
nt  case  series  described  this  virus  as  the  main  risk  factor
ssociated  with  hepatocellular  carcinoma.  Table  1  describes
hese  and  other  epidemiologic  characteristics  related  to  this
athology.  The  presence  of  underlying  hepatopathy  in  the
ases  of  HCC  varies  from  55%7 to  92%,12 a  ﬁgure  in  accor-
ance  with  internationally  published  ﬁgures.
The  presence  of  advanced  ﬁbrosis  without  cirrhosis  asso-
iated  with  hepatitis  B  and  C  virus  infections  has  been
eported  to  be  a  possible  etiologic  factor  for  developing
CC.13 It  should  be  underlined  that  there  is  a  higher  risk
ssociated  with  inﬂammatory  activity  and  a  greater  viral
urden  in  the  presence  of  chronic  virus  B  infection.  How-
ver,  this  does  not  appear  to  be  a  frequent  cause  of  HCC
n  Mexico,  where  the  prevalence  of  this  infection  is  consid-
red  low  (HBsAg  < 2%  in  the  general  population)  according  to
he  World  Health  Organization.  In  addition,  universal  hep-
titis  B  vaccination  was  implemented  in  Mexico  in  1998,  and
nfants  born  in  that  year  and  those  that  followed  have  been
accinated,  resulting  in  coverage  above  80%  in  the  infant
opulation  for  the  year  2007,  according  to  the  ofﬁcial  web-
ite  of  that  organization.
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Obesity  is  another  recognized  factor  that  predisposes  to
n  increase  in  the  incidence  of  different  cancers,  including
CC.  This  tumor  is  4.5%  more  frequent  in  men  with  a  BMI
bove  35  and  1.7%  more  frequent  in  women  with  a  BMI  above
5,  compared  with  normal-weight  subjects.1 The  presence
f  diabetes  mellitus  is  a  frequent  ﬁnding,  particularly  in
ases  of  cryptogenic  cirrhosis,  which  in  turn,  can  be  sec-
ndary  to  nonalcoholic  fatty  liver  disease,  and  therefore  its
ausal  role  in  HCC  is  not  clearly  deﬁned.  Other  risk  factors
escribed  for  the  development  of  HCC  include  iron  toxicity,
ﬂatoxin  exposure,  Wilson  disease,  alpha-1-antitrypsin  deﬁ-
iency,  and  other  metabolic  disorders  whose  prevalence  in
exico  is  unknown.
Recommendations:
 HCC  incidence  in  Mexico  has  increased  over  the  last  few
decades  (23/24  =  95.8%).
 The  mean  age  for  HCC  presentation  in  Mexico  is  in  the
sixth  decade  of  life  and  the  woman:man  ratio  appears  to
be  equal  (22/24  =  91.6%).
 HCC  is  frequently  associated  with  underlying  hepatopathy
(23/24  =  95.8%).
 Chronic  hepatitis  C  virus  infection  is  the  main  cause  of
HCC  reported  in  Mexico  (22/24  =  91.6%).
 Chronic  hepatitis  B  virus  infection  does  not  appear  to  be
a  frequent  cause  of  HCC  in  Mexico,  whereas  cirrhosis  due
to  nonalcoholic  fatty  liver  disease  may  emerge  in  the  near
future  as  an  important  cause  of  HCC  in  Mexico  (23/24  =
95.8%).
 Hereditary  metabolic  diseases  are  a  very  infrequent  cause
of  HCC  in  Mexico  (23/24  =  95.8%).
 There  is  no  available  data  on  aﬂatoxin  exposure  in  the
Mexican  population  (23/24=  95.8%).
I.  Surveillance and diagnosis
.  Aguirre  García,  M.  Castillo  Barradas,  R.  Contreras
man˜a,  L.  Ladrón  de  Guevara,  J.M.  Remes-Troche,  M.C.
epeda-Florencio
urveillance
creening  consists  of  the  application  of  minimally  invasive
ests  that  enable  early-stage  disease  detection,  allowing
urative  treatment  to  be  offered  and  thus  improving  the
urvival  rate.  In  the  high-risk  population  for  HCC,  lesions  <
 cm  are  considered  potentially  curable.  Surveillance  is  the
rogrammed  application  of  these  screening  tests  to  this  risk
roup.
Surveillance  is  carried  out  by  the  attending  physician  of
atients  with  chronic  liver  disease  (cirrhosis),  a  high-risk
roup  for  developing  HCC.14,15
HCC  surveillance  requires  a  multidisciplinary  team  that
ncludes  hepatologists,  radiologists,  and  pathologists  specif-
cally  trained  in  the  detection  and  study  of  space-occupying
esions  of  the  liver.
The  most  widely  used  screening  study  is  transabdo-
inal  ultrasound.  It  is  a  simple,  relatively  inexpensive,
nd  minimally  invasive  study  with  approximately  65-80%
ensitivity  and  over  90%  speciﬁcity.  Despite  its  being
perator-dependent,  it  is  the  screening  study  recommended
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y  the  current  international  guidelines,16--18 in  the  absence
f  a  more  effective  biomarker,19,20 and  approach  algorithms
re  available  in  the  event  of  an  abnormal  study.  According
o  a  recent  meta-analysis  carried  out  by  Singal  et  al.,21 the
ddition  of  alpha-fetoprotein  to  this  strategy  is  of  minimal
eneﬁt  and  raises  costs.  Abdominal  ultrasound  is  recom-
ended  every  6  months,  even  though  the  ideal  interval  is
nknown.  It  is  believed  that  a  period  of  4  to  12  months  is
eeded  for  an  undetectable  lesion  to  become  identiﬁable
2  cm)  by  this  method  and  undergo  curative  treatment.  In
ontrast,  performing  the  study  at  shorter  intervals  (every
hree  months)  increases  the  frequency  of  abnormal  ﬁndings,
ithout  modifying  the  survival  rate  of  those  patients  with
onﬁrmed  and  treated  tumors.22
A  frequent  ultrasound  ﬁnding  is  an  echogenic  nodule  sur-
ounded  by  a  hypoechogenic  halo,  and  when  Doppler  color
ltrasound  is  applied,  aberrant  intratumor  vascularity  can
e  observed.19,23,24 However,  it  should  be  emphasized  that
ny  recently  appearing  or  not  previously  identiﬁed  nodule
erits  evaluation.  Routine  AFP  determination  is  not  rec-
mmended  as  an  isolated  screening  and  surveillance  test
ecause  it  is  not  cost-effective.19,25--27
Surveillance  is  indicated  in  high-risk  groups,  speciﬁcally
n  patients  with  cirrhosis  of  the  liver  of  any  etiology,  with
ufﬁcient  liver  reserve  (Child-Pugh  stage  A  and  B)  and  ade-
uate  functional  capacity.  Contrastingly,  screening  for  HCC
s  not  recommended  for  patients  with  Child-Pugh  C  cirrhosis
f  the  liver,  except  in  patients  considered  for  placement  on
 waiting  list  for  liver  transplantation.28
iagnosis
hen  a  nodule  smaller  than  one  centimeter  is  identi-
ed  through  abdominal  ultrasound  In  risk  groups  under
urveillance,  an  ultrasound  study  every  3-4  months  is  rec-
mmended  for  a  period  of  18-24  months.  If  there  is  growth
n  the  morphologic  behavior  of  the  image  during  this  follow-
p  period,  a  dynamic  study  such  as  multiphase  computed
omography  or  nuclear  magnetic  resonance  should  be  car-
ied  out.16,29
To  be  considered  technically  adequate,  dynamic  stud-
es  should  include  the  following  phases:  non-contrast  phase,
epatic  artery  phase,  portal  vein  phase,  and  late  phase.16,30
t  is  very  important  to  standardize  the  multiphase  dynamic
tudy  to  avoid  interpretation  variation  and  errors.
The  choice  between  computed  axial  tomography  (CAT)  or
agnetic  resonance  depends  on  experience  and  availability
n  relation  to  each  hospital  center.  The  typical  dynamic  study
mage  of  an  HCC  tumor  is  a  hypo/isodense  lesion  in  the  non-
ontrast  phase  that  is  stronger  in  the  early  arterial  phase
nd  has  an  early  venous  washout.16
In  a  high-risk  population,  a  dynamic  study  with  an  image
ypical  of  an  HCC  lesion  is  sufﬁcient  for  making  HCC  diagno-
is.  If  the  image  is  atypical,  another  dynamic  study  should  be
arried  out;  if  the  studies  are  not  concordant,  then  the  rec-
mmendation  is  to  perform  a  liver  biopsy.16,17,31 Biopsy  is  not
ustiﬁed  in  high-risk  groups  with  nodules  regarded  as  typical
esions,  and  likewise,  biopsy  is  not  indicated  in  patients  that
re  not  candidates  for  any  speciﬁc  type  of  treatment.16,17
If  a  patient  without  cirrhosis  has  a  lesion  that  is  impos-
ible  to  diagnose  through  imaging  studies,  biopsy  of  the
-
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esion  is  always  recommended.31 Ultrasound-guided  or  CT-
uided  Tru-Cut  biopsy  is  suggested  and  should  always  be
eviewed  by  a  pathologist  with  training  and/or  experience
n  hepatic  lesions.  When  the  liver  biopsy  is  difﬁcult  to  inter-
ret,  histochemistry  studies  can  be  used,  such  as  reticulum
taining  and  immunohistochemistry  with  CD  34,  glypican-3,
eat  shock  protein  70,  and  glutamine  synthetase.  Unfortu-
ately,  the  majority  of  these  are  not  available  for  routine
se;  their  foremost  value  is  in  distinguishing  between  regen-
ration  nodule,  dysplastic  nodule,  and  HCC.31,32
According  to  current  management
ecommendations,16,17,22 the  determination  of  alpha-
etoprotein  levels  has  no  diagnostic  usefulness,  even  though
t  could  be  useful  in  evaluating  treatment  response  if  levels
ere  initially  high.
There  are  7  proposals  in  regard  to  staging  and  they
nclude  the  TNM  classiﬁcation  system  created  by  the  Amer-
can  Joint  Committee  on  Cancer  (AJCC),  the  Cancer  of  the
iver  Italian  Program  (CLIP),  the  Japanese  Integrated  System
JIS),  the  Grupe  d’Etude  de  Traitment  du  Carcinoma  Hep-
tocellulaire  (GRETCH),  the  Chinese  University  Prognostic
ndex  (CUPI),  the  Okuda  system,  and  the  Barcelona  Clinic
iver  Cancer  (BCLC)  system.  Traditionally,  tumor  progno-
is  is  directly  related  to  its  size  and  extension,  but  in  the
ase  of  HCC,  liver  function  reserve  also  affects  outcome
nd  limits  treatment.  Therefore,  the  ideal  classiﬁcation
hould  include  variables  related  to  the  tumor,  as  well  as
iver  function  classiﬁcation  and  functional  capacity  of  the
ndividual  presenting  with  2  diseases,  cirrhosis  and  cancer,
nd  ﬁnally,  it  should  include  the  efﬁcacy  of  the  treat-
ent  that  was  administered.  The  Okuda,  TNM,  CLIP,  and
IS  classiﬁcations  do  not  include  variables  that  evaluate  the
unctional  status  of  the  individual,  limiting  their  prognostic
apacity.  Both  the  CUPI  and  the  GRETCH  consider  indirect
iver  function  reserve  data.  Of  these  7  systems,  the  only
cale  that  includes  the  abovementioned  points  is  the  BCLC,
riginally  published  in  1999.33 Marrero  et  al.34 compared
he  7  different  existing  scales  in  a  consecutive  cohort  of
39  individuals  with  HCC  and  found  that  the  main  indepen-
ent  survival  predictors  were  tumor  diameter,  the  presence
f  portal  vein  thrombosis,  the  Model  of  End  Stage  Liver
iseases  (MELD)  score,  the  functional  capacity  of  the  indi-
idual,  and  the  administered  treatment.  Of  the  7  scales,
he  BCLC  had  the  greatest  independent  survival  predictive
ower,  because  all  these  parameters  are  included  in  its
ariables,  and  therefore  it  is  the  staging  classiﬁcation  rec-
mmended  by  the  American  and  European  guidelines,  as
ell  as  by  our  group.16,17 Even  though  recent  information
uggests  that  stage  B  (intermediate)  may  be  sufﬁciently  het-
rogeneous  to  merit  being  a  subclassiﬁcation,  this  remains
o  be  deﬁned  in  the  future.35
Recommendations:
 Surveillance  is  recommended  for  groups  at  high  risk  for
developing  HCC  in  Child-Pugh  stages  A or  B,  and  also  stage
C,  but  only  if  the  patient  is  on  a  waiting  list  or  considered
a  candidate  for  liver  transplantation  (22/24  =  91.6%). Surveillance  for  risk  groups  should  be  carried  out  with
abdominal  ultrasound  every  six  months  (23/24  =  95.8%).
 All  new  lesions  or  those  not  previously  identiﬁed  in  high-
risk  patients  merit  an  initial  evaluation  with  either  a
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aFigure  1  Liver  resection  algorithm  based  on  a  pa
multiphase  computed  tomography  or  nuclear  magnetic
resonance  dynamic  study  (23/24  =  95.8%).
-  A  dynamic  study  with  a  characteristic  lesion  >  1  cm  in
a  high-risk  population  is  sufﬁcient  for  making  diagnosis
(23/24  =  95.8%).
-  A  dynamic  study  with  an  undetermined  lesion  in  this  popu-
lation  makes  another  dynamic  study  or  guided  liver  biopsy
obligatory  (23/24  =  95.8%).
-  Any  recently  appearing  lesion  in  a  healthy  liver  that  can-
not  be  diagnosed  through  an  imaging  study  merits  a  liver
biopsy  (20/24  =  83.3%).
III. Curative treatment
F.J.  Bosques  Padilla,  M.  Guerrero  Hernández,  R.J.
Mondragón  Sánchez,  J.F.  Rivera  Ramos,  J.F.  Sánchez  Ávila,
M.  Vilatobá  Chapa
Three  curative  treatment  approaches,  in  accordance
with  BCLC  classiﬁcation,  are  available:  liver  resection,  liver
transplantation,  and  local  ablation.  In  general  terms,
liver  resection  is  the  treatment  of  choice  in  individuals  with
HCC  in  a  healthy  liver  and  is  an  excellent  alternative  for
individuals  with  cirrhosis,  following  strict  criteria  that  will
be  discussed  shortly.  In  the  presence  of  cirrhosis  and  under
e
i
t
st  with  hepatocellular  carcinoma  and  healthy  liver.
he  Milan  criteria,36 liver  transplantation  is  the  treatment
f  choice,  given  that  it  treats  not  only  the  tumor,  but  also
he  underlying  disease.  The  great  disadvantage,  particularly
n  Mexico,  is  in  relation  to  the  availability  of  this  strat-
gy.  Finally,  if  liver  transplantation  is  contraindicated  and
alls  outside  of  the  surgical  criteria,  the  alternative  cura-
ive  treatment  is  locoregional  therapy.  Of  these  therapies,
adiofrequency  ablation  (RFA)  achieves  the  best  results  in
elation  to  tumor  control  and  survival.  A  description  of  each
f  the  strategies  follows.
urgical  treatment
esection
ealthy  liver.  Patients  with  HCC  that  arises  in  a  healthy
iver  should  be  considered  for  surgical  resection  provided
hat  extrahepatic  disease  is  excluded  through  thoracic  and
bdominal  CAT  scans  and  bone  scintigraphy,  and  a  remnant
iver  volume  (RLV)  that  is  documented  through  tomography-
ssisted  volumetry,  is  taken  into  consideration.37,38 If  the
stimated  RLV  is  <  30%,  portal  embolization  is  suggested
n  order  to  increase  it  (ﬁgure  1).39--41 Some  authors  believe
hat  RLV  values  of  20%  are  adequate,  but  nevertheless,  it
hould  be  kept  in  mind  that  this  method  can  overestimate
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Table  2  Risk  factors  for  post-resection  liver  failure.
Above  70  years  of  age
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Adapted from Clavien et al.42
he  real  hepatic  volume.  Other  added  risk  factors  associ-
ted  with  post-resection  liver  failure  should  also  be  taken
nto  account  individually,  always  in  centers  with  experience
n  liver  surgery  (table  2).39,42
In  addition,  it  is  very  uncommon  for  HCC  to  present  in  a
iver  with  no  underlying  pathology,  and  thus  the  importance
f  evaluating  the  presence  of  ﬁbrosis,  steatosis,  or  steato-
epatitis  in  the  patient  being  considered  for  resection.  When
here  is  doubt,  non-neoplastic  liver  tissue  biopsy  should
e  performed  before  the  procedure.43 Furthermore,  each
atient  should  be  treated  individually  in  relation  to  comor-
idity.  The  surgical  technique  should  be  carefully  evaluated,
dentifying  the  cases  that  are  «high  complexity» ones  from
he  surgical  perspective.  Such  cases  can  result  in  a  period
f  prolonged  hepatic  ischemia  (Pringle  maneuver)  or  abun-
ant  intraoperative  blood  loss,  both  of  which  are  important
ntraoperative  predictive  factors  for  the  development  of
ostoperative  liver  failure.44,45
Portal  embolization  can  be  carried  out  percutaneously  or
uring  a  laparotomy,  ligating  the  desired  portal  branch  under
uoroscopic  guidance.46,47 The  aim  is  to  favor  the  hypertro-
hy  of  the  liver  tissue  that  will  be  the  future  remnant  by
xcluding  the  embolized  section  to  be  resected.  At  approxi-
ately  6  to  8  weeks  after  embolization,  a  new  triphasic  CAT
can  with  new  volume  measurements  is  carried  out  to  cal-
ulate  the  new  RLV.  If  the  desired  minimum  is  not  achieved,
he  patient  is  not  a  good  candidate  for  liver  resection.46--48
irrhotic  Liver.  The  individual  with  HCC  that  has  a  local-
zed  lesion,  cirrhosis  of  the  liver  with  Child-Pugh  stage  A
nd  no  evidence  of  portal  hypertension,  normal  bilirubin,
nd  a  RLV  >  50%,  is  a  candidate  for  liver  resection.33,44,45
nfortunately,  a  minority  of  cases  are  diagnosed  in  this
hase  and  the  surgery  must  also  be  performed  in  centers
hat  specialize  in  liver  surgery.  Anatomic  resection  should
e  carried  out,  if  possible,  as  it  has  shown  greater  sur-
ival  and  lower  recurrence  rates.49,50 If  ample  resection
s  considered  (>50%),  under  ideal  circumstances,  in  addi-
ion  to  the  above-stated,  the  indocyanine  green  retention
est  should  be  carried  out51,52 (ﬁgure  2);  lamentably,  this
ynamic  liver  function  test  is  not  available  in  Mexico.  There-
ore,  the  decision  to  perform  surgery  and  its  extension
epends  on  the  previously  mentioned  parameters  and  must
e  carried  out  in  centers  that  have  experience  in  hepatic
urgery  management,33,53,54 given  that  current  standards  in
enters  that  perform  tumor  resection  in  patients  with  cir-
hosis  include  mortality  <  3%,  transfusions  <  10%,  and  5-year
urvival  of  at  least  50%.55,56 According  to  different  meta-
nalyses,  5-year  survival  in  these  patients  is  above  50%,  and
an  reach  80%  in  super-selected  patients  (well-compensated
•
iigure  2  Liver  resection  algorithm  based  on  a  patient  with
epatocellular  carcinoma  and  cirrhosis  of  the  liver.
iver  disease  with  lesions  <  2  cm).57 Unfortunately,  tumor
ecurrence,  whether  true  or  de  novo, is  frequent  and  ﬂuc-
uates  between  60  and  100%  at  5  years,  because  cirrhosis,
he  main  risk  factor,  remains  and  progresses.44 We  did  not
nd  many  published  reports  on  the  national  statistics  of  liver
esection  due  to  HCC  in  Mexican  cirrhotic  patients.
iver  Transplantation
s  mentioned  above,  liver  transplantation  is  an  excellent
lternative,  but  its  availability  is  scarce  in  Mexico.  There-
ore  experience  is  limited  and  recommendations  are  based
n  international  consensuses.  In  general  terms,  patients
ith  advanced  cirrhosis  of  the  liver  that  meet  the  Milan
r  UCSF  criteria  are  regarded  as  candidates  for  liver
ransplantation.58--60 Staging  should  be  carried  out  through
horacic  and  abdominal  CAT  scan  and  bone  scintigraphy.
Milan  criteria:36
 One  lesion  <  de  5  cm
 Three  lesions,  none  of  which  are  >  3  cm
UCSF  criteria:59
One  lesion  <  6.5  cm
Two  to  3  lesions,  none  of  which  are  >  4.5  cm,  with  a  total
diameter  <  8  cm
Waiting  list  organ  assignation  is  done  according  to  patient
isease  severity  and  priority  is  given  to  those  that  have  a
reater  probability  of  dying.  The  MELD  classiﬁcation  is  used
or  this  because  patients  with  HCC  can  present  with  stable
isease.  The  MELD  score  does  not  reﬂect  disease  severity  or
he  risk  for  death  from  tumor  progression,  and  so  the  points
re  deﬁned  as  follows:61
 HCC  >  2  cm:  22  MELD  points  at  the  time  of  enrollment
(points  are  added  every  3  months  to  the  waiting  list,  with
a  10%  increase  in  risk  for  death) HCC  <  2  cm:  no  additional  points  are  ﬁgured  in
Because  HCC  patients  are  expected  to  be  on  the  wait-
ng  list  for  more  than  6  months,  locoregional  therapies  (RFA
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Thus  it  can  be  concluded  that  RFA  is  the  best  ablative
treatment  alternative,  but  with  the  following  limitations:  it
cannot  be  used  on  tumors  that  are  located  close  to  other
organs  (colon,  gallbladder,  etc.)  or  a large  blood  vessel,
because  of  the  possibilities  of  heat  damage  and  incomplete
ablation.  Moreover,  approximately  10-15%  of  the  tumors  that
are  difﬁcult  to  treat  with  RFA,  can  be  treated  with  PEI.84
Recommendations:
-  In  cases  of  liver  resection  due  to  HCC  in  a  healthy  liver,  a
meticulous  tumor  staging  study  and  an  abdominal  tomo-
graphy  scan  for  remnant  liver  volume  determination  are
essential  (23/24  =  95.8%).
-  Because  HCC  is  frequently  associated  with  underlying  hep-
atopathy,  in  the  case  of  resection,  the  underlying  hepatic
alteration  should  be  documented  through  liver  biopsy  if  it
has  not  been  previously  recorded  (22/24  =  91.6%).
-  In  situations  of  HCC  in  the  patient  with  cirrhosis,  liver
resection  is  an  option,  but  it  is  only  recommended  in  well-
selected  patients  with  good  functional  status  (23/24  =
95.8%).
-  Liver  transplantation  is  an  excellent  option  in  well-
selected  patients  that  has  the  advantage  of  restoring  liver
function  and  removing  the  neoplasia,  when  based  on  the
Milan  and  UCSF  criteria  (23/24  =  95.8%).
-  Percutaneous  ethanol  injection  and  radiofrequency  abla-
tion  are  two  options  for  tumor  destruction  that  are
available  in  Mexico  and  they  offer  good  therapeutic
response  when  performed  on  well-selected  patients  in
centers  with  adequate  experience  in  liver  surgery  (23/
24  =  95.8%).
III. Non-curative treatment
L.E.  Cisneros  Garza,  G.  Elizondo  Rojas,  F.D.  Huitzil  Melén-
dez,  O.  Quiroz  Castro,  T.  Rizo  Robles,  M.  Serna  Camacho
The  treatment  goal  for  advanced-stage  HCC  patients  is
to  increase  survival  (stages  B  and  C)  and/or  palliate  the
related  symptoms  (stage  D).  The  patients  that  are  sus-
ceptible  to  receiving  non-curative  treatment  are  those  in
categories  B  (intermediate),  C  (advanced),  and  D  (termi-
nal)  of  the  BCLC  classiﬁcation.  As  commented  beforehand,
the  different  stages  are  deﬁned  according  to  tumor  charac-
teristics,  liver  reserve  determined  through  the  Child-Pugh
classiﬁcation,  and  functional  classiﬁcation  by  the  ECOG
scale  (table  3).
Table  3  Eastern  Cooperative  Oncology  Group  (ECOG)  func-
tional  classiﬁcation.
Grade  Description
0  Asymptomatic,  functional,  and  independent
1 Symptomatic,  restricted  in  physically  strenuous
activity,  but  ambulatory  and  able  to  work.
2 Conﬁned  to  bed  or  chair  <  50%  of  waking  hours
3 Conﬁned  to  bed  >  50%  of  waking  hoursMexican  consensus  on  the  diagnosis  and  management  of  hep
or  transarterial  chemoembolization)  are  a  good  «treatment
bridge» option  if  liver  function  allows  it  (Child-Pugh  A  or
B).17,60,62 Stage  can  be  lowered  provided  that  the  aim  of
tumor  size  reduction  is  met,  staying  within  the  Milan  or
UCSF  criteria.63--65 Liver  transplantation  can  be  regarded  as
«salvage  therapy» in  patients  that  underwent  previous  liver
resection  and  then  presented  with  recurrence.66
Live  donor  liver  transplantation  between  2  adults  can  be
a  good  option  in  relation  to  HCC.  The  same  guidelines  for
cadaveric  donor  transplantation  should  be  followed  exactly
and  the  donor  should  be  clearly  aware  of  the  risks  and  pos-
sible  complications.60,67
Even  though  it  is  difﬁcult  to  compare  liver  resection  vs
liver  transplantation,  it  has  been  determined  that  patients
that  undergo  transplantation  present  with  greater  5-year
survival  (70%)  and  lower  disease  recurrence  frequency
(20%),  under  the  selection  criteria  mentioned  above.68--70
Locoregional  treatment
Ablative  therapies
Ablative  therapies  are  regarded  as  curative  strategies  in
those  patients  with  cirrhosis  and  early-stage  HCC  (Child-
Pugh  A-B,  with  a  solitary  nodule  ≤  3  cm  or  3  nodules  ≤
3  cm)  in  whom  surgical  treatment,  whether  resection  or  liver
transplantation,  are  contraindicated.17
These  therapies  are  based  on  the  injection  of  substances
into  the  tumor  (acetic  acid,  ethanol)  or  in  changes  of
temperature  (RFA,  laser,  cryotherapy)  that  lead  to  tumor
necrosis/destruction.71,72
The  2  most  frequent  strategies  used  are  percutaneous
ethanol  injection  (PEI)  and  RFA,  insofar  as  other  techniques
such  as  microwave  ablation,  cryoablation,  and  irreversible
electroporation  are  still  being  evaluated.  The  percutaneous
route  is  employed  in  the  majority  of  cases,  but  in  certain
speciﬁc  situations  the  procedures  may  be  performed  laparo-
scopically.
PEI  can  achieve  complete  necrosis  in  90%  of  the  tumors
<  2  cm  in  diameter.  However,  results  are  considerably  lower
with  larger  lesions.71,73 The  main  limitation  of  PEI  is  the  high
local  recurrence  rate,  reaching  43%  in  lesions  >  3  cm.74
RFA  has  been  more  widely  assessed  than  PEI  as  treatment
in  this  group  of  patients.  It  is  believed  that  the  energy  that
is  generated,  producing  coagulative  tumor  necrosis,  could
also  eliminate  small,  undetected  satellite  lesions,  achieving
better  tumor  control  with  fewer  sessions.  Numerous  studies
in  favor  of  this  have  compared  the  efﬁcacy  and  safety  of
the  two  techniques;  better  local  disease  control  has  consis-
tently  been  shown  with  RFA  vs  PEI  (2-year  local  recurrence
rates  of  2-18%  vs  11-45%).75--77 Furthermore,  3  independent
meta-analyses  that  included  all  randomized  studies  con-
ﬁrmed  that  RFA  beneﬁts  survival,  compared  with  PEI,  in
tumors  >  2 cm.78--80 The  best  results  with  RFA  are  obtained  in
patients  presenting  with  cirrhosis,  Child-Pugh  A,  and  small
solitary  tumors  (usually  <  2  cm),  with  a  5-year  survival  rate
of  40  to  70%.81,82
Some  studies  have  reported  a  higher  major  complication
rate  with  RFA  (4%;  95%  CI:  1.8-6.4%),  when  compared  with
PEI  (2.7%;  95%  CI:  0.4-5.1%).80 Nevertheless,  both  proce-
dures  are  considered  safe  in  general,  with  no  statistically
signiﬁcant  difference  in  major  adverse  events.83
4 Totally  conﬁned  to  bed  100%  of  the  time
5 Dead
Adapted from Oken et al.101
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physical  performance  status.  The  treatment  of  choice  is
transarterial  chemoembolization  (21/24  =  87.5%).
-  Stage  C  (advanced)  is  deﬁned  by  being  outside  of  cura-58  
Multidisciplinary  evaluation  is  recommended  for  the  cat-
gory  B  patient  to  determine  whether  he  or  she  is  a
andidate  for  liver  transarterial  chemoembolization.16,17
Early-stage  HCC  is  not  heavily  vascularized  and  its  blood
upply  comes  from  the  portal  vein.  Once  the  tumor  grows,
he  blood  supply  is  arterialized,  and  thus  obstruction  of  the
epatic  artery  in  this  disease  phase  is  an  effective  therapeu-
ic  procedure  for  treating  HCC.  Acute  arterial  obstruction
nduces  ischemic  necrosis  of  the  tumor.  This  obstruction
f  the  hepatic  artery  is  performed  by  an  interventionist
adiologist  and  is  carried  out  through  an  angiographic  pro-
edure  called  arterial  embolization.  When  this  procedure
s  combined  with  the  injection  of  chemotherapeutic  agents
hrough  the  same  hepatic  artery,  and  generally  mixed  with
ipiodol,  it  is  known  as  transarterial  chemoembolization.
mbolization  can  be  carried  out  with  a  series  of  solid  agents,
he  most  widely  used  of  which  are  polyvinyl  alcohol  parti-
les;  the  mixture  of  doxorubicin  with  lipiodol  is  used  as  a
hemotherapeutic  agent.85
The  patients  with  the  following  characteristics  are  con-
idered  candidates  for  this  procedure:
.  In  terms  of  liver  functionality,  patients  with  Child-Pugh
category  A  are  eligible.
.  In  terms  of  tumor  extension,  the  eligible  patients  are
those  that  do  not  have  the  possibility  of  curative  treat-
ment  because  they  present  with  a lesion  >  5  cm  or
multinodular  disease  (more  than  3  nodules  >  3  cm)  and
no  advanced  disease  data,  meaning  no  portal  invasion  or
extrahepatic  metastasis.
.  In  terms  of  physical  performance  status,  patients  with
an  ECOG  score  of  0,  which  implies  no  physical  limitation,
are  eligible.
Chemoembolization  is  recommended  as  ﬁrst-line  non-
urative  treatment  in  patients  with  multifocal  lesions  >
 cm  that  do  not  present  with  vascular  invasion  or  extra-
epatic  dissemination  and  that  have  good  liver  reserve.
ecause  it  has  been  demonstrated  that  chemoemboliza-
ion  beneﬁts  overall  survival  in  this  group  of  patients,  it  is
ecommended  that  all  centers  treating  patients  with  HCC
e  equipped  with  the  human  and  technical  resources  for
erforming  this  procedure.86 There  is  still  no  consensus  in
elation  to  the  number  of  sessions  for  the  patient  to  undergo
r  their  frequency;  this  information  requires  further  study.87
nd  ﬁnally,  different  techniques  are  being  developed,  such
s  radioembolization88,89 and  drug-releasing  solid  particle
hemoembolization;90,91 because  they  are  currently  being
valuated  there  is  still  not  enough  evidence  available  to  be
ble  to  give  a  recommendation.
The  category  C  patient  should  undergo  a  multidisciplinary
valuation  to  determine  whether  he  or  she  is  eligible  for
eceiving  speciﬁc  molecular  targeting  treatment  with  the
ultikinase  inhibitor,  sorafenib.  Sorafenib  is  currently  con-
idered  the  ﬁrst-line  treatment  for  patients  with  advanced
CC,  and  it  is  the  only  systemic  therapy  that  has  been
pproved  for  use  in  this  disease,16,17 by  demonstrating  that  it
rolongs  survival  in  advanced-stage  patients,  compared  with
lacebo  (7.9  vs  10.9  months;  p  <  0.001).92 There  is  evidence
f  certain  signaling  pathway  alteration  in  these  tumor  cells,
ncluding  the  Raf/MEK/ERK  and  VEGF  pathways.93 Likewise,
orafenib  is  a  multikinase  inhibitor  that  targets  Raf-1,M.S.  González  Huezo,  J.F.  Sánchez  Ávila
-Raf,  vascular  endothelial  growth  factor  receptor
VEGFR2),  platelet-derived  growth  factor  receptor  (PDGFR),
nd  c-Kit  receptors,  and  inhibits  tyrosine  kinase  and  serine-
hreonine  kinase  receptors,  acting  as  an  anti-proliferative
nd  anti-angiogenic  agent.  Its  signiﬁcant  effect  on  overall
urvival  and  tumor  progression  time  were  documented
n  a  phase  II  study94 and  in  the  pivotal  phase  III  SHARP
tudy  published  in  the  New  England  Journal  of  Medicine
n  2008.92Patients  with  the  following  characteristics  are
andidates  for  systemic  sorafenib  therapy:16,17
)  In  terms  of  liver  functionality  the  patients  with  Child-
Pugh  category  A  are  eligible.
)  In  terms  of  tumor  extension  the  patients  with  data  of
advanced  disease,  including  portal  invasion  and/or  extra-
hepatic  disease  are  eligible.
)  In  terms  of  physical  performance  patients  with  an  ECOG
score  of  0-2  are  eligible.
Patients  that  do  not  have  access  to  treatment  with
orafenib  could  be  evaluated  to  determine  their  eligibility
or  treatment  with  chemotherapy  or  with  emerging  pro-
ocols  in  clinical  research  analyzing  molecules.  Different
peciﬁc  molecular  targets  are  currently  being  developed  and
tudied,  but  there  is  not  yet  sufﬁcient  evidence  for  their
ecommendation.95--98
HCC  has  been  shown  to  be  chemo-resistant  to  the  major-
ty  of  chemotherapeutic  agents;  in  general  terms,  the
ntitumor  response  is  low  (0-18%)  and  there  is  no  evidence  of
urvival  improvement  with  either  their  isolated  or  combined
se.  The  liver  function  disorder  caused  by  cirrhosis  may  alter
he  metabolism  of  these  agents  and  increase  their  toxicity,
nd  so  they  are  not  recommended  for  routine  use  or  to  be
sed  outside  of  research  protocols.99,100
Finally,  patients  in  category  D,  deﬁned  as  terminal  stage,
ith  a  life  expectancy  of  about  3  months  and  characterized
y  an  ECOG  3-4  physical  performance  grade  and/or  Child-
ugh  stage  C,  should  receive  multidisciplinary  management.
t  should  be  focused  on  improving  quality  of  life  through
ymptomatic  palliative  management  that  includes  pain
reatment,  nutrition,  and  psychological  management.16,17
Recommendations:
 HCC  that  is  in  the  non-curative  stage  should  be  evaluated
by  a  multidisciplinary  team  of  experts  in  the  ﬁeld  (23/24
=  95.8%).
 Treatment  goals  in  stage  B  (intermediate)  and  stage  C
(advanced)  patients  include  prolonging  survival  and  dis-
ease  progression  time  (23/24  =  95.8%).
 Stage  B  (intermediate)  is  characterized  by  being  outside
of  curative  treatment,  but  with  no  evidence  of  vascular
or  extrahepatic  invasion,  and  with  good  liver  reserve  andtive  criteria,  presenting  with  vascular  invasion  and/or
extrahepatic  disease,  but  with  adequate  liver  reserve  and
physical  performance  status.  The  treatment  of  choice  is
systemic  therapy  with  sorafenib  (22/24  =  91.6%).
atoc
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Instituto  Mexicano  del  Seguro  Social,  Mexico  City.
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